These findings indicate that SLC31A1 upregulation associates with chemotherapy nonresponse and aggressive tumor grade specifically in TNBC and provided the rationale for evaluating dynamic systemic copper changes in the prospective cohort. This evidence concerns the gene SLC31A1 and neoplasm.